Contents
Special Issue Topic

Emerging Molecular Targets and Therapies of Genitourinary Tumors

Guest Editor

Dr. Alcides Chaux E-Mail

Director, Department of Scientific Research, Norte University, Paraguay

Research Keywords: Genitourinary Cancer, Molecular Oncology, Targeted Therapy, Cancer Genomics, Immune Response, Disease Progression, Treatment Resistance

About the Special lssue

The realm of genitourinary oncology is experiencing a significant shift, as research unveils an array of molecular targets and innovative therapies with the potential to redefine the management of these tumors.

As the scientific community gains a more profound understanding of the genetic and molecular foundations of urothelial, prostate, renal, and testicular cancers, there emerges a critical opportunity to shape the future of targeted therapies. The goal is to compile a series of works that not only identify novel genetic alterations and pathways but also discuss the latest therapeutic approaches, ranging from small molecule inhibitors to immune modulators and beyond.

Precision medicine is steering a course toward individualized treatment regimens, and this issue aims to highlight research that dissects the complex interplay of tumor genetics, host immune responses, and the microenvironment. The emphasis is on uncovering the mechanisms of disease initiation, progression, and resistance, with the ultimate objective of fostering improved clinical outcomes.

This collection is intended to act as a catalyst for new research, shed light on the potential of emerging molecular targets, and offer insights into the future of therapy for genitourinary malignancies.

The special issue aims to focus on the advancement of molecular targets and the development of new therapeutic strategies for genitourinary cancers. We welcome manuscripts that not only represent scientific breakthroughs but also have the potential to make a tangible difference in the clinical setting. 

Keywords: Genitourinary Cancer, Molecular Oncology, Targeted Therapy, Cancer Genomics, Immune Response, Disease Progression, Treatment Resistance

Published Articles

Open Access Short Communication
Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma
Ilya Tsimafeyeu ... Mark Gluzman
Published: April 01, 2025 Explor Target Antitumor Ther. 2025;6:1002305
2479 43 0
Open Access Review
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives
Irene Testi ... Ursula Vogl
Published: November 21, 2024 Explor Target Antitumor Ther. 2024;5:1326–1364
1537 53 0
Open Access Case Report
Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy
Min Woo Hwang ... Jeanny B. Aragon-Ching
Published: October 17, 2024 Explor Target Antitumor Ther. 2024;5:1261–1270
1209 24 0
Open Access Systematic Review
Diagnostic and prognostic role of NLR in testicular cancer
Shirin Sarejloo ... Brandon Lucke-Wold
Published: September 19, 2024 Explor Target Antitumor Ther. 2024;5:1177–1198
1135 26 1
Open Access Review
Emerging molecular therapies in the treatment of bladder cancer
Scott D. Bell ... Yujiang Fang
Published: August 29, 2024 Explor Target Antitumor Ther. 2024;5:1135–1154
1531 35 0
Open Access Commentary
The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC)
Minira Aslanova ... Jeanny B. Aragon-Ching
Published: July 29, 2024 Explor Target Antitumor Ther. 2024;5:971–980
1380 50 0
Open Access Review
Landscape of targeted therapies for advanced urothelial carcinoma
Shihao Shang ... Zheng Zhu
Published: June 21, 2024 Explor Target Antitumor Ther. 2024;5:641–677
1724 38 0